Biotech | October 28, 2021
MSD and MPP sign licensing agreement to make molnupiravir affordable
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
A total of 12 generic medicines have been included in the list
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
